Cargando…
Reducing return of disease activity in patients with relapsing multiple sclerosis transitioned from natalizumab to teriflunomide: 12-month interim results of teriflunomide therapy
BACKGROUND: Natalizumab is an effective treatment for relapsing multiple sclerosis. Return of disease activity upon natalizumab discontinuance creates the need for follow-up therapeutic strategies. OBJECTIVE: To assess the efficacy of teriflunomide following natalizumab discontinuance in relapsing m...
Autores principales: | Cohan, Stanley L, Edwards, Keith, Lucas, Lindsay, Gervasi-Follmar, Tiffany, O’Connor, Judy, Siuta, Jessica, Kamath, Vineetha, Garten, Lore, Chen, Chiayi, Thomas, James, Smoot, Kyle, Kresa-Reahl, Kiren, Spinelli, Kateri J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6350141/ https://www.ncbi.nlm.nih.gov/pubmed/30729028 http://dx.doi.org/10.1177/2055217318824618 |
Ejemplares similares
-
The results of a 24-month controlled, prospective study of relapsing multiple sclerosis patients at risk for progressive multifocal encephalopathy, who switched from prolonged use of natalizumab to teriflunomide
por: Cohan, Stanley, et al.
Publicado: (2021) -
Outcomes of Stable Multiple Sclerosis Patients Staying on Initial Interferon Beta Therapy Versus Switching to Another Interferon Beta Therapy: A US Claims Database Study
por: Cohan, Stanley, et al.
Publicado: (2018) -
An update of teriflunomide for treatment of multiple sclerosis
por: Oh, Jiwon, et al.
Publicado: (2013) -
Teriflunomide promotes oligodendroglial differentiation and myelination
por: Göttle, Peter, et al.
Publicado: (2018) -
Teriflunomide: Lack of efficacy: case report
Publicado: (2022)